SEATTLE (AP) -- Biotechnology drug developer Oncothyreon Inc. said Monday that Douglas E. Williams was named to its board.
Williams, 51, currently serves as chief executive of ZymoGenetics Inc. He previously held senior level positions at Seattle Genetics Inc., Immunex Corp. and Amgen Inc. He is also a director of Array BioPharma Inc. and Aerovance Inc.
Oncothyreon specializes in the development of therapies to treat cancer.
Shares gained 7 cents to close at $5.08. The stock has traded between 62 cents and $7.77 in the past 52 weeks and is up more than sixfold since the start of the year.
Copyright © 2009 The Associated Press. All rights reserved. The information contained in the AP News report may not be published, broadcast, rewritten, or redistributed without the prior written authority of The Associated Press.